WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 191

Legislative bill overview

SB 191 establishes a pilot program in Connecticut to study the therapeutic use of psychedelics (such as psilocybin and MDMA) in controlled clinical settings under professional supervision. The bill authorizes the state to license and regulate facilities, therapists, and protocols for psychedelic-assisted therapy while maintaining safety and research standards.

Why is this important

Psychedelic-assisted therapy shows promising clinical results for treatment-resistant depression, PTSD, and end-of-life anxiety, but remains federally illegal outside narrow research exceptions. This pilot program would position Connecticut as an early adopter of an emerging mental health treatment modality while generating state-specific safety and efficacy data.

Potential points of contention

  • Federal-state legal conflict: Psychedelics remain Schedule I controlled substances federally, creating legal risk for participants, therapists, and the state despite potential FDA pathways for exceptions
  • Clinical safety and oversight: Determining adequate training standards, dosing protocols, and psychological screening to prevent adverse outcomes requires detailed regulation not yet established
  • Equity and access: Pilot programs risk creating expensive treatments accessible only to wealthy participants, raising questions about who benefits and whether costs should be publicly subsidized

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.